-
公开(公告)号：US20230125046A1
公开(公告)日：2023-04-20
申请号：US17788663
申请日：2020-12-21
发明人： Qiang Zhang , Leifu Yang , Nanqiao Zheng , Shannan Yu , Yueming Sun , Zhenke Guo
IPC分类号： A61K31/506 , C07D239/48 , C07D401/12 , C07D401/14 , C07D405/14 , C07D417/14 , C07D213/84 , A61K31/5377 , A61K31/541 , A61K31/4545 , A61K31/496
摘要： A cyano-substituted pyridine and cyano-substituted pyrimidine compound and a preparation method therefor and an application thereof, which specifically relate to a compound represented by formula (I) and an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, and a prodrug thereof, and a preparation method therefor and an application thereof in the preparation of a drug as a kinase inhibitor. The compound has good inhibitory activity against kinases such as FGFR4 and mutant FGFR4V550L.
-
公开(公告)号：US11479559B2
公开(公告)日：2022-10-25
申请号：US16968793
申请日：2019-01-25
发明人： Qiang Zhang , Shannan Yu , Zhongxiang Wang , Shouye Feng , Yansheng Liu , Xingfu Li , Hongbo Zhang , Leifu Yang , Hailong Yang , Likai Zhou , Nanqiao Zheng , Chenming Hu , Zhanqiang Xu
IPC分类号： C07D491/056 , A61K31/4741 , A61K31/496 , A61K31/5377 , A61K31/54 , A61K45/06
摘要： The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase.
-
公开(公告)号：US20220002308A1
公开(公告)日：2022-01-06
申请号：US17293416
申请日：2019-11-15
发明人： Qiang Zhang , Shannan Yu , Yueming Sun , Leifu Yang , Nanqiao Zheng
IPC分类号： C07D491/056
摘要： Disclosed are a class of compounds as inhibitors of kinases such as TRK, c-MET, AXL, MER and/or VEGFR2, compositions and use thereof. In particular, disclosed are a class of compounds (as shown in formula (1)) or isomers, solvates, hydrates, pharmaceutically acceptable salts, and prodrugs thereof having strong inhibition activities for kinases such as TRK, c-MET, AXL, MER and/or VEGFR2, and pharmaceutical compositions comprising said compounds. Also disclosed is use of the compounds or pharmaceutical compositions in the preparation of a medicament for treating autoimmune diseases or cancers.
-
4.发明授权公开(公告)号：US11548900B2
公开(公告)日：2023-01-10
申请号：US16978158
申请日：2019-03-05
发明人： Qiang Zhang , Shannan Yu , Zhongxiang Wang , Shouye Feng , Nanqiao Zheng , Hailong Yang , Leifu Yang , Hongbo Zhang , Likai Zhou , Zhanqiang Xu
IPC分类号： C07D498/04 , C07D519/00 , A61K31/5383 , A61P1/00 , A61P1/16 , A61P9/10 , A61P11/00 , A61P17/00 , A61P17/06 , A61P17/14 , A61P19/02 , A61P19/08 , A61P27/02 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/06
摘要： Provided are an oxazino-quinazoline and oxazino-quinoline type compound, a preparation method, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, a prodrug thereof, a preparation method, and uses thereof in preparing a drug acting as a kinase inhibitor.
-
公开(公告)号：US11407760B2
公开(公告)日：2022-08-09
申请号：US16968797
申请日：2019-01-25
发明人： Qiang Zhang , Shannan Yu , Zhongxiang Wang , Shouye Feng , Yueming Sun , Yansheng Liu , Hongbo Zhang , Leifu Yang , Hailong Yang , Likai Zhou , Nanqiao Zheng , Chenming Hu , Zhanqiang Xu
IPC分类号： C07D491/056 , A61P35/02 , A61P35/04 , A61P35/00
摘要： The present invention relates to a dioxinoquinoline compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2 and c-MET) inhibitor is used for treating disorders related to tyrosine kinase.
-
公开(公告)号：US10980809B2
公开(公告)日：2021-04-20
申请号：US16489989
申请日：2018-02-11
发明人： Qiang Zhang , Hongbo Zhang , Leifu Yang , Hailong Yang , Likai Zhou , Nanqiao Zheng , Shannan Yu , Zhongxiang Wang , Shouye Feng , Zhanqiang Xu
IPC分类号： A61K31/517 , A61P35/00 , A61K31/4741 , C07D491/056
摘要： The present invention relates to a urea-substituted aromatic ring-linked dioxinoquinazoline and a urea-substituted aromatic ring-linked dioxinoquinoline of Formula (I), or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases.
-
7.发明申请公开(公告)号：US20210040114A1
公开(公告)日：2021-02-11
申请号：US16978158
申请日：2019-03-05
发明人： Qiang Zhang , Shannan Yu , Zhongxiang Wang , Shouye Feng , Nanqiao Zheng , Hailong Yang , Leifu Yang , Hongbo Zhang , Likai Zhou , Zhanqiang Xu
IPC分类号： C07D498/04 , C07D519/00
摘要： Provided are an oxazino-quinazoline and oxazino-quinoline type compound, a preparation method, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, a prodrug thereof, a preparation method, and uses thereof in preparing a drug acting as a kinase inhibitor.
-
公开(公告)号：US20200061065A1
公开(公告)日：2020-02-27
申请号：US16489989
申请日：2018-02-11
发明人： Qiang Zhang , Hongbo Zhang , Leifu Yang , Hailong Yang , Likai Zhou , Nanqiao Zheng , Shannan Yu , Zhongxiang Wang , Shouye Feng , Zhanqiang Xu
IPC分类号： A61K31/517 , C07D491/056 , A61K31/4741 , A61P35/00
摘要： The present invention relates to a urea-substituted aromatic ring-linked dioxinoquinazoline and a urea-substituted aromatic ring-linked dioxinoquinoline of Formula (I), or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.017 秒)
